UNSPSC 51332305: Pimozide

This classification denotes an antipsychotic agent with the molecular formula C28H29F2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1HIZ4DL86F, chemically known as 2h-benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- but generally known as pimozide, which bears US NIH Compound Identifier 16362. European Medicines Agency schedules Pimozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09847MIG.

UNSPSC 51332305 Pimozide is a Commodity code that nominally covers a specific antipsychotic medication, but recent state and local procurement activity shows little alignment with that narrow scope. The three recent opportunities tagged to this code involve naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative exploring direct-to-manufacturer prescription contracting (Texas Health and Human Services Commission), and a multistate cooperative purchasing agreement for generic pharmaceuticals and over-the-counter products (Minnesota Multistate Cooperative Purchasing Alliance). The code sees activity from county health departments, state health agencies, and multistate cooperative purchasing vehicles rather than traditional procurement offices, reflecting the healthcare and pharmaceutical distribution focus of the tagged opportunities. None of these solicitations directly concern pimozide or single-drug commodity procurement; the mismatch between the code's nominal scope and actual recent purchasing suggests either misclassification at submission or that pimozide procurement under this code tier is not currently active in state and local markets.

Geographic activity centers on Florida, Texas, and Minnesota based on the recent records. Seminole County's IFB (closing July 26, 2023) sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. Texas HHS issued an RFI (April 3, 2026) to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler arrangements. Minnesota's MMCAP cooperative purchasing RFP (due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local government facilities, requiring vendors to supply through authorized wholesalers and achieve market availability by May 15, 2026. No dollar values, set-aside designations, or repeat-buyer patterns emerge from the recent block. The code shows minimal decision-relevant activity for vendors targeting pimozide specifically.